• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Daratumumab monotherapy in relapsed and refractory multiple myeloma patients with severely compromised forced expiratory volume in one second.

作者信息

Kim Jin-Hyo, Park Sung-Soo, Yoon Jae-Ho, Lee Sung-Eun, Kim Hee-Je, Min Chang-Ki

机构信息

Department of Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

出版信息

Blood Res. 2022 Mar 31;57(1):76-80. doi: 10.5045/br.2022.2021183.

DOI:10.5045/br.2022.2021183
PMID:35342045
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8958367/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32a9/8958367/f0e048c12a37/br-57-1-76-f1a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32a9/8958367/f0e048c12a37/br-57-1-76-f1a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32a9/8958367/f0e048c12a37/br-57-1-76-f1a.jpg

相似文献

1
Daratumumab monotherapy in relapsed and refractory multiple myeloma patients with severely compromised forced expiratory volume in one second.达雷妥尤单抗单药治疗一秒用力呼气量严重受损的复发难治性多发性骨髓瘤患者。
Blood Res. 2022 Mar 31;57(1):76-80. doi: 10.5045/br.2022.2021183.
2
Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.达雷妥尤单抗用于初诊及复发/难治性多发性骨髓瘤的治疗：当前及新出现的疗法
Front Oncol. 2021 Feb 17;10:624661. doi: 10.3389/fonc.2020.624661. eCollection 2020.
3
Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients.达雷妥尤单抗单药治疗复发/难治性多发性骨髓瘤患者后的免疫调节剂药物和蛋白酶体抑制剂再治疗的疗效。
Br J Haematol. 2018 Oct;183(1):60-67. doi: 10.1111/bjh.15504. Epub 2018 Aug 6.
4
EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.EMA 对达雷妥尤单抗治疗多发性骨髓瘤成人患者的评估。
Oncologist. 2018 May;23(5):594-602. doi: 10.1634/theoncologist.2017-0328. Epub 2018 Jan 25.
5
Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice.简要报告：达雷妥尤单抗单药疗法在实际临床中紧急用于复发或难治性多发性骨髓瘤后的临床经验
Jpn J Clin Oncol. 2019 Jan 1;49(1):92-95. doi: 10.1093/jjco/hyy177.
6
Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma.达雷妥尤单抗单药治疗复发或难治性多发性骨髓瘤的真实世界中大量预处理患者的疗效。
Adv Med Sci. 2019 Sep;64(2):349-355. doi: 10.1016/j.advms.2019.05.001. Epub 2019 May 21.
7
Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma.皮下注射达雷妥尤单抗和透明质酸酶-fihj用于新诊断或复发/难治性多发性骨髓瘤
Ther Adv Hematol. 2021 Jan 22;12:2040620720987075. doi: 10.1177/2040620720987075. eCollection 2021.
8
Daratumumab Monotherapy for Relapsed or Refractory Multiple Myeloma: Results of an Early Access Treatment Protocol in Europe and Russia.达雷妥尤单抗单药治疗复发或难治性多发性骨髓瘤：欧洲和俄罗斯早期准入治疗方案的结果
Oncol Ther. 2021 Jun;9(1):139-151. doi: 10.1007/s40487-020-00137-x. Epub 2021 Feb 25.
9
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.卡非佐米、地塞米松和达雷妥尤单抗与卡非佐米和地塞米松治疗复发或难治性多发性骨髓瘤患者（CANDOR）：一项随机、多中心、开放性、3 期研究的结果。
Lancet. 2020 Jul 18;396(10245):186-197. doi: 10.1016/S0140-6736(20)30734-0.
10
Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group.达雷妥尤单抗治疗多发性骨髓瘤：多发性骨髓瘤 GIMEMA 拉齐奥组的经验。
Ann Hematol. 2021 Apr;100(4):1059-1063. doi: 10.1007/s00277-020-04374-y. Epub 2021 Feb 2.

本文引用的文献

1
Safety and efficacy of daratumumab in patients with multiple myeloma and severe renal failure.达雷妥尤单抗在多发性骨髓瘤合并严重肾衰竭患者中的安全性和有效性。
Br J Haematol. 2021 May;193(4):e33-e36. doi: 10.1111/bjh.17412. Epub 2021 Mar 21.
2
Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trial-unfit patients and subsequent therapy.达雷妥尤单抗单药治疗复发/难治性多发性骨髓瘤，重点关注不适合临床试验的患者和后续治疗。
Br J Haematol. 2021 Apr;193(1):101-112. doi: 10.1111/bjh.17071. Epub 2020 Dec 27.
3
Evaluation of Montelukast for the Prevention of Infusion-related Reactions With Daratumumab.
孟鲁司特钠预防达雷妥尤单抗相关输注反应的效果评价。
Clin Lymphoma Myeloma Leuk. 2020 Oct;20(10):e777-e781. doi: 10.1016/j.clml.2020.05.024. Epub 2020 Jun 7.
4
Daratumumab Monotherapy in Heavily Pretreated Asian Patients With Relapsed and Refractory Multiple Myeloma: A Real-world Experience.达雷妥尤单抗单药治疗复发/难治性多发性骨髓瘤的亚洲广泛预处理患者：真实世界经验。
Anticancer Res. 2019 Sep;39(9):5165-5170. doi: 10.21873/anticanres.13712.
5
Treatment of relapsed multiple myeloma: Evidence-based recommendations.复发性多发性骨髓瘤的治疗：循证推荐。
Blood Rev. 2020 Jan;39:100616. doi: 10.1016/j.blre.2019.100616. Epub 2019 Aug 31.
6
Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice.简要报告：达雷妥尤单抗单药疗法在实际临床中紧急用于复发或难治性多发性骨髓瘤后的临床经验
Jpn J Clin Oncol. 2019 Jan 1;49(1):92-95. doi: 10.1093/jjco/hyy177.
7
Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab.多发性骨髓瘤中新单克隆抗体输注反应的管理：达雷妥尤单抗和埃罗妥珠单抗。
J Oncol Pract. 2018 Jul;14(7):414-422. doi: 10.1200/JOP.18.00143.
8
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.达雷妥尤单抗单药治疗治疗难治性多发性骨髓瘤患者（SIRIUS）：一项开放标签、随机、2 期试验。
Lancet. 2016 Apr 9;387(10027):1551-1560. doi: 10.1016/S0140-6736(15)01120-4. Epub 2016 Jan 7.
9
Daratumumab: First Global Approval.达雷妥尤单抗：全球首次获批。
Drugs. 2016 Feb;76(2):275-81. doi: 10.1007/s40265-015-0536-1.
10
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.Daratumumab 单药治疗多发性骨髓瘤中针对 CD38。
N Engl J Med. 2015 Sep 24;373(13):1207-19. doi: 10.1056/NEJMoa1506348. Epub 2015 Aug 26.